Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
Journal Article
|Research
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy
Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...
Journal Article
|Research
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine
BACKGROUND
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...
Journal Article
|Research
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases
BACKGROUND
The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...
Conference Material
|Slide Presentation
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|Abstract
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Journal Article
|Research
2024-01-29 • medRxiv
2024-01-29 • medRxiv
BACKGROUND
Aft...
Technical Report
|Study report
2018-07-01
2018-07-01